抗体片段efgartigimod治疗重症肌无力:III期试验迎硕果!

2020-05-27 Allan MedSci原创

Argenx公司近日公布了抗体片段efgartigimod治疗重症肌无力(gMG)的III期临床(ADAPT研究)的最新数据,结果显示,efgartigimod已达到主要终点。

Argenx公司近日公布了抗体片段efgartigimod治疗重症肌无力(gMG)的III期临床(ADAPT研究)的最新数据,结果显示,efgartigimod已达到主要终点。Argenx首席医学官Wim Parys表示:“患者对efgartigimod产生了快速且深度的反应。此外,反应持续了超过8或12周”。

ADAPT试验招募了167例gMG患者,这些患者的MG-ADL总分达到或超过5分。不管参与者的乙酰胆碱受体抗体状态如何,都可以参加研究。在随机分组之前,他们还接受了至少一种gMG治疗药物,包括乙酰胆碱酯酶抑制剂、皮质类固醇或非类固醇免疫抑制药物。结果显示,在重症肌无力(QMG)评分方面,有63.1%的AChR-Ab+患者对efgartigimod有反应,而对安慰剂组仅有14.1%的患者有反应。

gMG是慢性的神经肌肉疾病,会造成不同程度的肌肉无力。最常影响眼部、脸部及吞咽相关的肌肉。会造成复视、眼睑下垂、说话困难及行走困难等症状。重症肌无力可能会突然发生。

 

原始出处:

https://www.firstwordpharma.com/node/1727148

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1009361, encodeId=2cdf1009361cc, content=<a href='/topic/show?id=910e959e0c9' target=_blank style='color:#2F92EE;'>#重症肌无力#</a>终于有药物治疗了<a href='/topic/show?id=67b110438e11' target=_blank style='color:#2F92EE;'>#艾加莫德#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95970, encryptionId=910e959e0c9, topicName=重症肌无力), TopicDto(id=104387, encryptionId=67b110438e11, topicName=艾加莫德)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Thu Aug 19 09:25:17 CST 2021, time=2021-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1009357, encodeId=7f8c100935e7f, content=<a href='/topic/show?id=19dc6559a4' target=_blank style='color:#2F92EE;'>#efgartigimod#</a>艾加莫德,厉害!, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6559, encryptionId=19dc6559a4, topicName=efgartigimod)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Thu Aug 19 09:20:37 CST 2021, time=2021-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1947745, encodeId=6a90194e745bf, content=<a href='/topic/show?id=24ef96066d' target=_blank style='color:#2F92EE;'>#II期试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9606, encryptionId=24ef96066d, topicName=II期试验)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKUdkK5dVTue7YQDvwqM1ugOuEpDZEzvXhoGClFiavehcrNAYDuPbks3MkKLPpyAEicgic80KguxwicYQ/132, createdBy=ec952500165, createdName=ms5187542471278033, createdTime=Sat Nov 07 15:25:16 CST 2020, time=2020-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916274, encodeId=c33819162e416, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Wed Mar 10 13:25:16 CST 2021, time=2021-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1357515, encodeId=c955135e515d4, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri May 29 06:25:16 CST 2020, time=2020-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1436670, encodeId=26c814366e00b, content=<a href='/topic/show?id=e7c18092578' target=_blank style='color:#2F92EE;'>#肌无力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80925, encryptionId=e7c18092578, topicName=肌无力)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Fri May 29 06:25:16 CST 2020, time=2020-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594746, encodeId=08b71594e460a, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9562, encryptionId=b317956200, topicName=III期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Fri May 29 06:25:16 CST 2020, time=2020-05-29, status=1, ipAttribution=)]
    2021-08-19 病毒猎手

    #重症肌无力#终于有药物治疗了#艾加莫德#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1009361, encodeId=2cdf1009361cc, content=<a href='/topic/show?id=910e959e0c9' target=_blank style='color:#2F92EE;'>#重症肌无力#</a>终于有药物治疗了<a href='/topic/show?id=67b110438e11' target=_blank style='color:#2F92EE;'>#艾加莫德#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95970, encryptionId=910e959e0c9, topicName=重症肌无力), TopicDto(id=104387, encryptionId=67b110438e11, topicName=艾加莫德)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Thu Aug 19 09:25:17 CST 2021, time=2021-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1009357, encodeId=7f8c100935e7f, content=<a href='/topic/show?id=19dc6559a4' target=_blank style='color:#2F92EE;'>#efgartigimod#</a>艾加莫德,厉害!, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6559, encryptionId=19dc6559a4, topicName=efgartigimod)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Thu Aug 19 09:20:37 CST 2021, time=2021-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1947745, encodeId=6a90194e745bf, content=<a href='/topic/show?id=24ef96066d' target=_blank style='color:#2F92EE;'>#II期试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9606, encryptionId=24ef96066d, topicName=II期试验)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKUdkK5dVTue7YQDvwqM1ugOuEpDZEzvXhoGClFiavehcrNAYDuPbks3MkKLPpyAEicgic80KguxwicYQ/132, createdBy=ec952500165, createdName=ms5187542471278033, createdTime=Sat Nov 07 15:25:16 CST 2020, time=2020-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916274, encodeId=c33819162e416, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Wed Mar 10 13:25:16 CST 2021, time=2021-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1357515, encodeId=c955135e515d4, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri May 29 06:25:16 CST 2020, time=2020-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1436670, encodeId=26c814366e00b, content=<a href='/topic/show?id=e7c18092578' target=_blank style='color:#2F92EE;'>#肌无力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80925, encryptionId=e7c18092578, topicName=肌无力)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Fri May 29 06:25:16 CST 2020, time=2020-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594746, encodeId=08b71594e460a, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9562, encryptionId=b317956200, topicName=III期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Fri May 29 06:25:16 CST 2020, time=2020-05-29, status=1, ipAttribution=)]
    2021-08-19 病毒猎手

    #efgartigimod#艾加莫德,厉害!

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1009361, encodeId=2cdf1009361cc, content=<a href='/topic/show?id=910e959e0c9' target=_blank style='color:#2F92EE;'>#重症肌无力#</a>终于有药物治疗了<a href='/topic/show?id=67b110438e11' target=_blank style='color:#2F92EE;'>#艾加莫德#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95970, encryptionId=910e959e0c9, topicName=重症肌无力), TopicDto(id=104387, encryptionId=67b110438e11, topicName=艾加莫德)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Thu Aug 19 09:25:17 CST 2021, time=2021-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1009357, encodeId=7f8c100935e7f, content=<a href='/topic/show?id=19dc6559a4' target=_blank style='color:#2F92EE;'>#efgartigimod#</a>艾加莫德,厉害!, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6559, encryptionId=19dc6559a4, topicName=efgartigimod)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Thu Aug 19 09:20:37 CST 2021, time=2021-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1947745, encodeId=6a90194e745bf, content=<a href='/topic/show?id=24ef96066d' target=_blank style='color:#2F92EE;'>#II期试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9606, encryptionId=24ef96066d, topicName=II期试验)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKUdkK5dVTue7YQDvwqM1ugOuEpDZEzvXhoGClFiavehcrNAYDuPbks3MkKLPpyAEicgic80KguxwicYQ/132, createdBy=ec952500165, createdName=ms5187542471278033, createdTime=Sat Nov 07 15:25:16 CST 2020, time=2020-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916274, encodeId=c33819162e416, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Wed Mar 10 13:25:16 CST 2021, time=2021-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1357515, encodeId=c955135e515d4, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri May 29 06:25:16 CST 2020, time=2020-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1436670, encodeId=26c814366e00b, content=<a href='/topic/show?id=e7c18092578' target=_blank style='color:#2F92EE;'>#肌无力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80925, encryptionId=e7c18092578, topicName=肌无力)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Fri May 29 06:25:16 CST 2020, time=2020-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594746, encodeId=08b71594e460a, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9562, encryptionId=b317956200, topicName=III期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Fri May 29 06:25:16 CST 2020, time=2020-05-29, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1009361, encodeId=2cdf1009361cc, content=<a href='/topic/show?id=910e959e0c9' target=_blank style='color:#2F92EE;'>#重症肌无力#</a>终于有药物治疗了<a href='/topic/show?id=67b110438e11' target=_blank style='color:#2F92EE;'>#艾加莫德#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95970, encryptionId=910e959e0c9, topicName=重症肌无力), TopicDto(id=104387, encryptionId=67b110438e11, topicName=艾加莫德)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Thu Aug 19 09:25:17 CST 2021, time=2021-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1009357, encodeId=7f8c100935e7f, content=<a href='/topic/show?id=19dc6559a4' target=_blank style='color:#2F92EE;'>#efgartigimod#</a>艾加莫德,厉害!, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6559, encryptionId=19dc6559a4, topicName=efgartigimod)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Thu Aug 19 09:20:37 CST 2021, time=2021-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1947745, encodeId=6a90194e745bf, content=<a href='/topic/show?id=24ef96066d' target=_blank style='color:#2F92EE;'>#II期试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9606, encryptionId=24ef96066d, topicName=II期试验)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKUdkK5dVTue7YQDvwqM1ugOuEpDZEzvXhoGClFiavehcrNAYDuPbks3MkKLPpyAEicgic80KguxwicYQ/132, createdBy=ec952500165, createdName=ms5187542471278033, createdTime=Sat Nov 07 15:25:16 CST 2020, time=2020-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916274, encodeId=c33819162e416, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Wed Mar 10 13:25:16 CST 2021, time=2021-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1357515, encodeId=c955135e515d4, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri May 29 06:25:16 CST 2020, time=2020-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1436670, encodeId=26c814366e00b, content=<a href='/topic/show?id=e7c18092578' target=_blank style='color:#2F92EE;'>#肌无力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80925, encryptionId=e7c18092578, topicName=肌无力)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Fri May 29 06:25:16 CST 2020, time=2020-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594746, encodeId=08b71594e460a, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9562, encryptionId=b317956200, topicName=III期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Fri May 29 06:25:16 CST 2020, time=2020-05-29, status=1, ipAttribution=)]
    2021-03-10 juliusluan78
  5. [GetPortalCommentsPageByObjectIdResponse(id=1009361, encodeId=2cdf1009361cc, content=<a href='/topic/show?id=910e959e0c9' target=_blank style='color:#2F92EE;'>#重症肌无力#</a>终于有药物治疗了<a href='/topic/show?id=67b110438e11' target=_blank style='color:#2F92EE;'>#艾加莫德#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95970, encryptionId=910e959e0c9, topicName=重症肌无力), TopicDto(id=104387, encryptionId=67b110438e11, topicName=艾加莫德)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Thu Aug 19 09:25:17 CST 2021, time=2021-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1009357, encodeId=7f8c100935e7f, content=<a href='/topic/show?id=19dc6559a4' target=_blank style='color:#2F92EE;'>#efgartigimod#</a>艾加莫德,厉害!, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6559, encryptionId=19dc6559a4, topicName=efgartigimod)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Thu Aug 19 09:20:37 CST 2021, time=2021-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1947745, encodeId=6a90194e745bf, content=<a href='/topic/show?id=24ef96066d' target=_blank style='color:#2F92EE;'>#II期试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9606, encryptionId=24ef96066d, topicName=II期试验)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKUdkK5dVTue7YQDvwqM1ugOuEpDZEzvXhoGClFiavehcrNAYDuPbks3MkKLPpyAEicgic80KguxwicYQ/132, createdBy=ec952500165, createdName=ms5187542471278033, createdTime=Sat Nov 07 15:25:16 CST 2020, time=2020-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916274, encodeId=c33819162e416, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Wed Mar 10 13:25:16 CST 2021, time=2021-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1357515, encodeId=c955135e515d4, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri May 29 06:25:16 CST 2020, time=2020-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1436670, encodeId=26c814366e00b, content=<a href='/topic/show?id=e7c18092578' target=_blank style='color:#2F92EE;'>#肌无力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80925, encryptionId=e7c18092578, topicName=肌无力)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Fri May 29 06:25:16 CST 2020, time=2020-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594746, encodeId=08b71594e460a, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9562, encryptionId=b317956200, topicName=III期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Fri May 29 06:25:16 CST 2020, time=2020-05-29, status=1, ipAttribution=)]
    2020-05-29 zhaojie88
  6. [GetPortalCommentsPageByObjectIdResponse(id=1009361, encodeId=2cdf1009361cc, content=<a href='/topic/show?id=910e959e0c9' target=_blank style='color:#2F92EE;'>#重症肌无力#</a>终于有药物治疗了<a href='/topic/show?id=67b110438e11' target=_blank style='color:#2F92EE;'>#艾加莫德#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95970, encryptionId=910e959e0c9, topicName=重症肌无力), TopicDto(id=104387, encryptionId=67b110438e11, topicName=艾加莫德)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Thu Aug 19 09:25:17 CST 2021, time=2021-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1009357, encodeId=7f8c100935e7f, content=<a href='/topic/show?id=19dc6559a4' target=_blank style='color:#2F92EE;'>#efgartigimod#</a>艾加莫德,厉害!, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6559, encryptionId=19dc6559a4, topicName=efgartigimod)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Thu Aug 19 09:20:37 CST 2021, time=2021-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1947745, encodeId=6a90194e745bf, content=<a href='/topic/show?id=24ef96066d' target=_blank style='color:#2F92EE;'>#II期试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9606, encryptionId=24ef96066d, topicName=II期试验)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKUdkK5dVTue7YQDvwqM1ugOuEpDZEzvXhoGClFiavehcrNAYDuPbks3MkKLPpyAEicgic80KguxwicYQ/132, createdBy=ec952500165, createdName=ms5187542471278033, createdTime=Sat Nov 07 15:25:16 CST 2020, time=2020-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916274, encodeId=c33819162e416, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Wed Mar 10 13:25:16 CST 2021, time=2021-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1357515, encodeId=c955135e515d4, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri May 29 06:25:16 CST 2020, time=2020-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1436670, encodeId=26c814366e00b, content=<a href='/topic/show?id=e7c18092578' target=_blank style='color:#2F92EE;'>#肌无力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80925, encryptionId=e7c18092578, topicName=肌无力)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Fri May 29 06:25:16 CST 2020, time=2020-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594746, encodeId=08b71594e460a, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9562, encryptionId=b317956200, topicName=III期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Fri May 29 06:25:16 CST 2020, time=2020-05-29, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1009361, encodeId=2cdf1009361cc, content=<a href='/topic/show?id=910e959e0c9' target=_blank style='color:#2F92EE;'>#重症肌无力#</a>终于有药物治疗了<a href='/topic/show?id=67b110438e11' target=_blank style='color:#2F92EE;'>#艾加莫德#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95970, encryptionId=910e959e0c9, topicName=重症肌无力), TopicDto(id=104387, encryptionId=67b110438e11, topicName=艾加莫德)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Thu Aug 19 09:25:17 CST 2021, time=2021-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1009357, encodeId=7f8c100935e7f, content=<a href='/topic/show?id=19dc6559a4' target=_blank style='color:#2F92EE;'>#efgartigimod#</a>艾加莫德,厉害!, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6559, encryptionId=19dc6559a4, topicName=efgartigimod)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Thu Aug 19 09:20:37 CST 2021, time=2021-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1947745, encodeId=6a90194e745bf, content=<a href='/topic/show?id=24ef96066d' target=_blank style='color:#2F92EE;'>#II期试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9606, encryptionId=24ef96066d, topicName=II期试验)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKUdkK5dVTue7YQDvwqM1ugOuEpDZEzvXhoGClFiavehcrNAYDuPbks3MkKLPpyAEicgic80KguxwicYQ/132, createdBy=ec952500165, createdName=ms5187542471278033, createdTime=Sat Nov 07 15:25:16 CST 2020, time=2020-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916274, encodeId=c33819162e416, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Wed Mar 10 13:25:16 CST 2021, time=2021-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1357515, encodeId=c955135e515d4, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri May 29 06:25:16 CST 2020, time=2020-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1436670, encodeId=26c814366e00b, content=<a href='/topic/show?id=e7c18092578' target=_blank style='color:#2F92EE;'>#肌无力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80925, encryptionId=e7c18092578, topicName=肌无力)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Fri May 29 06:25:16 CST 2020, time=2020-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594746, encodeId=08b71594e460a, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9562, encryptionId=b317956200, topicName=III期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Fri May 29 06:25:16 CST 2020, time=2020-05-29, status=1, ipAttribution=)]

相关资讯

没有肢体乏力,怎么就重症肌无力危象了?

无肢体无力、无眼睑下垂,患者被诊断为重症肌无力,其诊断依据是什么?

JAMA Neurol:利妥昔单抗治疗新发全身性重症肌无力

利妥昔单抗治疗新发全身性重症肌无力的临床疗效显著优于常规免疫抑制剂

Anesth Analg :ugammadex对重症肌无力患者术后肌无力危象的影响

因为重症肌无力(MG)患者术后肌无力危象和残余神经肌肉阻断剂(NMBA)可导致呼吸衰竭,因此其需要机械通气。然而,尚不清楚使用Sugammadex逆转NMBA是否能减少MG患者手术后的肌无力危象。我们利用全国住院患者数据库分析了Sugammadex与MG患者术后肌无力危象的关系。

利润低、原料缺 这些药医院短缺

这些药,医院紧缺。 ▍这些药,医院急着采购 5月20日,广东省珠海市香洲区人民医院公布《紧缺药品询价公告》。 一批药网上无法供货,所以要采购。通过公开询价、经销商报价、遴选最低价,报价后公示3个工作日,要求经销商务必在公示期限后五个工作日内按询价结果及时送货。清单如下

2019 意大利建议: 重症肌无力的诊断和治疗

重症肌无力是一种可或得很好治疗的疾病,在大多数患者中,经过及时诊断和恰当治疗可以使症状得到满意的控制。本文的主要内容涉及 重症肌无力的诊断和治疗。

AAN:Immunovant宣布其用于治疗重症肌无力的抗FcRn单抗IMVT-1401,在健康受试者中耐受良好

2019年美国神经病学学会(AAN)年会上,生物制药公司Immunovant宣布其IMVT-1401在健康受试者中的详细研究结果。

拓展阅读

JAMA Neurology:复旦华山医院开展治疗全身性肌无力症的巴托利单抗与安慰剂比较研究

巴托利单抗提高了全身型MG成人患者MG-ADL持续改善率,且耐受性良好。

肌肉力量恢复,症状持续改善18个月!CAR-T疗法为重症肌无力患者带来新希望

研究初步展现了BCMA CAR-T疗法在MG治疗中的良好耐受性和安全性以及持久的临床疗效。

重症肌无力患者的麻醉管理要点

我们在临床麻醉中会遇到此类患者,只要我们抓住其中的重点,就可使患者安全度过围术期,增加患者的安全性。

PN:中国儿童期重症肌无力的临床特征、治疗和预后因素

重症肌无力(MG)是一种自身免疫性神经肌肉疾病,儿童期发病的MG称为儿童期MG(CMG),多数CMG患者临床症状轻微,预后良好,尤其是发病年龄早、病程短、AChR-ab阴性的患者。

一文读懂:常见重症肌无力严重程度量表

重症肌无力(myasthenia gravis,MG)是由自身抗体主要是乙酰胆碱受体抗体(acetylcholine receptor antibody,AChR)结合于神经-肌肉接头突触后膜组分产生

再鼎医药重症肌无力新药皮下注射剂型艾加莫德α注射液国内申报上市

7月8日,CDE官网显示,再鼎医药艾加莫德α注射液(皮下注射,efgartigimod PH20 SC)上市申请获受理,推测适应症为全身型重症肌无力。